(Q54654144)

English

Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C

scientific article published on August 24, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C (English)

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

author name string

Avanti Verma

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

Justin Degrado

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

Adam B. Hittelman

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735383

22 June 2024

Marcia A. Wheeler

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735383

22 June 2024

Hristos Z. Kaimakliotis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735383

22 June 2024

Robert M. Weiss

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735383

22 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20735383

22 June 2024

publication date

24 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1464-410X.2010.09543.x

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.09543.x/fullpdf

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

107

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

7

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

1154-1161

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

BCG immunotherapy of bladder cancer: 20 years on.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

VEGF receptor expression and signaling in human bladder tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

New wirings in the survivin networks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

Targeting angiogenesis in bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09543.X

21 January 2018

The global burden of urinary bladder cancer.

2

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma

5

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy

10

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors

11

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer

13

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation

14

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder

15

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Urine detection of survivin and diagnosis of bladder cancer

17

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome

18

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer

21

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer

27

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder

28

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma

38

1 reference

10.1111/J.1464-410X.2010.09543.X

https://api.crossref.org/works/10.1111/J.1464-410X.2010.09543.X

22 June 2024

Identifiers

10.1111/J.1464-410X.2010.09543.X

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20735383

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54654144&oldid=2185957823"